Akros SCHK HK-Korea Low Volatility Factor Index

The ex-dividend date for the interim dividend is August 21, 2026, with payment scheduled for September 8, 2026. Medium importance is estimated as the dividend yield is expected to cause a price impact between 5% and 10%, expected.

Q2 2026 earnings release scheduled; analysts forecast a significant profit increase driven by improved investment returns, which is expected to have a medium impact (~5%) scheduled.

Yuhan Corp is scheduled to release its Q2 2026 earnings results on August 18, 2026. Analysts forecast the results will meet market expectations, supported by a one-time milestone payment of KRW 44.9 billion for the European commercialization of Lazertinib, with estimated revenue of KRW 634.4 billion and operating profit of KRW 66.5 billion forecasted. This event is scheduled.

KT Corporation is scheduled to announce its Q2 2026 earnings results on or around August 18, 2026, with analysts forecasting operating profit to be below market consensus. Importance is estimated at Medium as an earnings miss typically impacts price by ~5%. scheduled

Q2 2026 earnings release; Low importance estimated as a routine financial disclosure, scheduled.

Woori Financial Group's Board approved a comprehensive share exchange on 2026-04-24 to acquire all remaining Tongyang Life Insurance shares and make Tongyang Life a wholly owned subsidiary. The exchange is expected to issue 8,696,875 new Woori Financial shares to Tongyang Life minority shareholders, changing Woori Financial's outstanding share count.

Q2 2026 earnings release scheduled. Analysts forecast strong performance, potentially a record-high quarterly operating profit, driven by cost efficiencies and B2B growth, scheduled.

Ex-dividend date for the semi-annual cash dividend of KRW 250 per share, scheduled for payment on August 20, 2026, scheduled.

First-ever quarterly dividend ex-date on July 30, 2026, with record date July 31 and payment of KRW 210 per share on August 28, 2026; Low importance estimated as a routine yield event, scheduled.

KT&G is scheduled to release its earnings for the second quarter of 2026 on July 29, 2026. Analysts forecast revenue of 1.7 trillion KRW and operating profit of 400 billion KRW. High importance is estimated as results exceeding consensus typically drive a price impact of 10% or more, forecasted.

KRAFTON is scheduled to release its earnings results for Q2 2026 and the first half of 2026 on July 29, 2026. High importance is estimated due to the potential for significant price impact exceeding 10% scheduled

Samsung Card is scheduled to release its Q2 2026 earnings on July 28, 2026; 5% impact estimated based on historical volatility, scheduled.

High importance is estimated as the buyback size typically triggers a >10% price impact. Q2 2026 earnings release is scheduled for 2026-07-24. Analysts forecast a net profit of around KRW 1.2-1.3 trillion and expect the announcement of a share buyback and cancellation plan of at least KRW 500 billion forecasted.

Woori Financial Group is scheduled to announce its Q2 2026 earnings results on 2026-07-24. Analysts forecast a recovery from Q1, with net profit estimated around KRW 958.1 billion. A medium impact is estimated as the market anticipates a rebound, scheduled.

Shinhan Financial Group is scheduled to announce its Q2 2026 earnings on July 23, 2026. Analysts forecast a year-over-year increase in net profit to approximately KRW 1.6-1.7 trillion. High importance is justified by the potential for a 10% price impact following the announcement, estimated and scheduled.

Q2 2026 earnings release scheduled. Analysts forecast a 15-19% year-over-year decrease in net profit, attributed to the absence of one-off gains from the previous year, higher funding costs, and increased loan loss provisions; a Medium importance is expected.

Q2 2026 earnings release scheduled for 2026-07-23. Analysts forecast revenue of approximately 1.32 trillion KRW and operating profit of 600 billion KRW forecasted.

Disclosure of a financial incident involving suspected fraud of approximately KRW 83.3 billion at a Chinese subsidiary on July 16, 2026; Medium importance estimated due to the significant scale of the loss, scheduled.

On July 15, 2026, the company completed its shareholder return policy by cancelling approximately KRW 500 billion worth of its own shares (treasury stock). High importance is justified by the anticipated 10% price impact from this significant reduction in shares outstanding.

Partner company Johnson & Johnson announced on July 15, 2026, that global sales of the Rybrevant and Lazcluze (Lazertinib) combination therapy grew 60.8% year-over-year to $289 million in Q2 2026, indicating strong market uptake and a positive outlook for Yuhan's royalty income.

The company is expected to announce the Korean Ministry of Food and Drug Safety (MFDS) approval for a Phase 1 clinical trial of CT-P68 on July 15, 2026; low importance is estimated as early-stage clinical trials typically have limited immediate price impact, expected.

Announced a major organizational restructuring for H2 2026 to strengthen focus on the Busan-Ulsan-Gyeongnam regional economy, ESG strategy, and future finance initiatives like AI and digital assets.